Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

Born Free video highlights how humans are to blame for COVID-19

News Story 1
 Wildlife charity Born Free has released a video emphasising the importance of changing the ways in which humans treat wildlife in order to prevent pandemics from occurring in the future.

The video, narrated by founder patron Joanna Lumley OBE, says: "To deal with the very immediate threat of another global catastrophe, we have to focus on ending the destruction and conversion of natural habitats and the devastating impact of the wildlife trade.

"The vast majority of these viruses originated in wild animals before infecting us. Destroying and exploiting nature puts us in closer contact with wildlife than ever before."

Born Free has compiled an online resource with information on how to take action and improve protections for wildlife here.

To view the video, please click here.

Images (c) Jan Schmidt-Burbach. 

Click here for more...
News Shorts
RVC opens 2021 Summer Schools applications

The Royal Veterinary College (RVC) has opened applications for its 2021 Summer Schools, with students in Years 10, 11 and 12 invited to apply.

Taking place between July and August 2021, the event gives budding vets from all backgrounds first-hand insight into what it's like to study at the Campus.

Much of this year's content is likely to be delivered virtually, including online lectures and practical demonstrations, but the RVC hopes to welcome each of the participants to campus for at least one day to gain some hands-on experience.

For more information about the Schools and to apply, visit: rvc.uk.com/SummerSchools Applications close on the 2 March 2021.